Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Leukemia, Myeloid, Acute 5Myelodysplastic Syndromes 3Leukemia, Myelomonocytic, Chronic 2Targeted Therapy 1Spinal Cord Neoplasms 1Oligodendroglioma 1Myeloproliferative Disorders 1Myeloid Malignancies 1Glioma 1Glioblastoma 1Diffuse Intrinsic Pontine Glioma 1Brain Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 5Radiotherapy 2Bevacizumab 2tozuleristide 1olutasidenib 1abemaciclib 1Radiation 1Nivolumab 1Megestrol Acetate 1Lomustine 1Lapatinib 1Irinotecan 1Immunoglobulin G 1Fluorodeoxyglucose F18 1Disulfides 1Cyproheptadine 1Chemotherapy, Adjuvant 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Spinal Cord Neoplasms × olutasidenib × Clear all
NCT06161974 2025-02-21

Study of Olutasidenib and Temozolomide in HGG

Rigel Pharmaceuticals

Phase 2 Recruiting
60 enrolled
CNS

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Spinal Cord Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡